The Hyderabad-based firm had posted a net loss of Rs 28.54 crore for the corresponding period of previous fiscal.
Consolidated net sales of the company rose to Rs 1,551.95 crore for the third quarter, as compared to Rs 1,263.73 crore for the same period of 2011-12 fiscal, Aurobindo Pharma Ltd said in a statement.
"We continue to see traction on our performance both in sales and earnings on year on year basis on account of improved business mix in formulations from new product approvals and launches in the US market," Aurobindo Pharma Ltd Managing Director N Govindarajan said.
He added that during the quarter, the US Food and Drug Administration (USFDA) cleared its two units and the health regulator has started approving products from these facilities.
"These will pave the way for consolidating injectable formulations business," Govindarajan added.
The company said its board also approved an interim dividend of 100 per cent, Re 1 per equity share of Re 1 for the year 2012-13.
Shares of Aurobindo Pharma today ended at Rs 186.55 on the BSE, down 3.07 per cent from their previous close.